참고문헌
- Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attentiondeficit/ hyperactivity disorder. Expert Rev Neurother 2009;9:1121-1131. https://doi.org/10.1586/ern.09.65
- Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009;23:194-205. https://doi.org/10.1177/0269881108089809
- McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:351-356. https://doi.org/10.1089/cap.2006.16.351
- Choi EM. ‛Smart drug?' Caution on abuse and misuse of ADHD mediaction. Money Today 2011 Nov 1. Available from http://news.mt.co.kr/mtview.php?no=2011110110544791407&type=1
- Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: Views from developmental psychology. Dev Neuropsychol 1988;4:199-230. https://doi.org/10.1080/87565648809540405
- Smith EE, Jonides J. Storage and executive processes in the frontal lobes. Science 1999;283:1657-1661. https://doi.org/10.1126/science.283.5408.1657
- Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94. https://doi.org/10.1037/0033-2909.121.1.65
- Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628. https://doi.org/10.1038/nrn896
- Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005;57: 1336-1346. https://doi.org/10.1016/j.biopsych.2005.02.006
- Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009;302:1084-1091. https://doi.org/10.1001/jama.2009.1308
- Johansen EB, Killeen PR, Russell VA, Tripp G, Wickens JR, Tannock R, et al. Origins of altered reinforcement effects in ADHD. Behav Brain Funct 2009;5:7. https://doi.org/10.1186/1744-9081-5-7
- Kobel M, Bechtel N, Weber P, Specht K, Klarhöfer M, Scheffler K, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009;13:516-523. https://doi.org/10.1016/j.ejpn.2008.10.008
- Kemner C, Jonkman LM, Kenemans JL, Böcker KB, Verbaten MN, Van Engeland H. Sources of auditory selective attention and the effects of methylphenidate in children with attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:776-778. https://doi.org/10.1016/j.biopsych.2003.12.007
- Lufi D, Parish-Plass J, Gai E. The effect of methylphenidate on the cognitive and personality functioning of ADHD children. Isr J Psychiatry Relat Sci 1997;34:200-209.
- Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:191-198. https://doi.org/10.1097/00004583-200402000-00015
- Kuhle HJ, Kinkelbur J, Andes K, Heidorn FM, Zeyer S, Rautzenberg P, et al. Self-regulation of visual attention and facial expression of emotions in ADHD children. J Atten Disord 2007;10:350-358. https://doi.org/10.1177/1087054706289944
- Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 2006;30: 1225-1245. https://doi.org/10.1016/j.neubiorev.2006.10.002
- Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl) 1993;111:1-16. https://doi.org/10.1007/BF02257400
- Hink RF, Fenton WH Jr, Tinklenberg JR, Pfefferbaum A, Kopell BS. Vigilance and human attention under conditions of methylphenidate and secobarbital intoxication: an assessment using brain potentials. Psychophysiology 1978;15:116-125. https://doi.org/10.1111/j.1469-8986.1978.tb01346.x
- Coons HW, Peloquin LJ, Klorman R, Bauer LO, Ryan RM, Perlmutter RA, et al. Effect of methylphenidate on young adult's vigilance and event-related potentials. Electroencephalogr Clin Neurophysiol 1981;51:373-387. https://doi.org/10.1016/0013-4694(81)90101-2
- Aman MG, Vamos M, Werry JS. Effects of methylphenidate in normal adults with reference to drug action in hyperactivity. Aust N Z J Psychiatry 1984;18:86-88. https://doi.org/10.3109/00048678409161040
- Strauss J, Lewis JL, Klorman R, Peloquin LJ, Perlmutter RA, Salzman LF. Effects of methylphenidate on young adults' performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology 1984;21:609-621. https://doi.org/10.1111/j.1469-8986.1984.tb00247.x
- Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 1997;131:196-206. https://doi.org/10.1007/s002130050284
- Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000;20:RC65.
- Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 2004;161:1173-1180. https://doi.org/10.1176/appi.ajp.161.7.1173
- Tomasi D, Volkow ND, Wang GJ, Wang R, Telang F, Caparelli EC, et al. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Neuroimage 2011;54:3101-3110. https://doi.org/10.1016/j.neuroimage.2010.10.060
- Ozaki TJ. Frontal-to-parietal top-down causal streams along the dorsal attention network exclusively mediate voluntary orienting of attention. PLoS One 2011;6:e20079. https://doi.org/10.1371/journal.pone.0020079
- Tomasi D, Volkow ND. Aging and functional brain networks. Mol Psychiatry 2012;17:471, 549-558.
- Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;10:410-422. https://doi.org/10.1038/nrn2648
- U.S. Food and Drug Administration. Psychiatric Adverse Events Associated with Drug Treatment of ADHD: Review of Postmarketing Safety Data. Maryland: U.S. Food and Drug Administration;2006.
- Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003;64 Suppl 11:14-18. https://doi.org/10.4088/JCP.v64n0105
- Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008;165:604-609. https://doi.org/10.1176/appi.ajp.2008.07091465
- Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165:597-603. https://doi.org/10.1176/appi.ajp.2007.07091486
- Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. https://doi.org/10.1001/archpedi.160.1.82
- Friedman RA. The changing face of teenage drug abuse--the trend toward prescription drugs. N Engl J Med 2006;354:1448-1450. https://doi.org/10.1056/NEJMp068010
- McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100:96-106. https://doi.org/10.1111/j.1360-0443.2005.00944.x
- Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004;5:421-425. https://doi.org/10.1038/nrn1390
- Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008;456:702-705. https://doi.org/10.1038/456702a
- Sannerud C, Feussner G. Is Ritalin an abused drug? Does it meet the criteria of a Schedule II substance? In: Greenhill LL, Osman BB, editors. Ritalin, theory and practice. 2nd ed. New Rochelle, NY: Mary Ann Liebert;2000. p.27-44.
피인용 문헌
- Simultaneous Determination of Methylphenidate, Amphetamine and their Metabolites in Urine using Direct Injection Liquid Chromatography-Tandem Mass Spectrometry vol.5, pp.4, 2014, https://doi.org/10.5478/MSL.2014.5.4.104
- Proper administration of psychostimulants vol.61, pp.8, 2018, https://doi.org/10.5124/jkma.2018.61.8.502
- Pharmacological treatment for attention deficit hyperactivity disorder in adults vol.64, pp.1, 2012, https://doi.org/10.5124/jkma.2021.64.1.49